Identification of Novel Protein Kinase Receptor Type 2 Inhibitors Using Pharmacophore and Structure-Based Virtual Screening-Reference-Cited by-同舟云学术

Identification of Novel Protein Kinase Receptor Type 2 Inhibitors Using Pharmacophore and Structure-Based Virtual Screening

Published:2018-02-18 Issue:2 Volume:23 Page:453
ISSN:1420-3049
Container-title:Molecules
language:en
Short-container-title:Molecules

Author:

Cruz Josiane,Neto Moysés,Silva Luciane,da S. Ramos Ryan,da S. Costa Josivan,Brasil Davi,Lobato Cleison,da Costa Glauber,Bittencourt José,da Silva Carlos,Leite Franco,Santos Cleydson

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Link

http://www.mdpi.com/1420-3049/23/2/453/pdf

Reference59 articles.

1. In Vivo Inhibition of RIPK2 Kinase Alleviates Inflammatory Disease

2. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors

3. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

4. Ponatinib-induced neutrophilic panniculitis

5. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Study of Pyracantha crenulata Phytoconstituents for their Anti-Diabetic Activity Using Computational Techniques;Current Analytical Chemistry;2024-06

2. Analgesic Activity of 5-Acetamido-2-Hydroxy Benzoic Acid Derivatives and an In-Vivo and In-Silico Analysis of Their Target Interactions;Pharmaceuticals;2023-11-09

3. RIPK2 inhibitors for disease therapy: Current status and perspectives;European Journal of Medicinal Chemistry;2023-11

4. Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target;Journal of Medicinal Chemistry;2023-10-19

5. Ponatinib: An update on its drug targets, therapeutic potential and safety;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09